Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

JW (Cayman) Therapeutics Co. Ltd. (HK:2126)

HKEX:2126

2126

JW (Cayman) Therapeutics Co. Ltd.

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding HK:2126?

Track your performance easily

Link Broker

JW (Cayman) Therapeutics Co. Ltd. (2126) Stock Price & Analysis

0 Followers

2126 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$1.19 - HK$3.49

Previous CloseHK$1.38

Volume279.50K

Average Volume (3M)1.13M

Market Cap

HK$573.30M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Mar 19, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.67

Shares OutstandingN/A

10 Day Avg. Volume699,848

30 Day Avg. Volume1,128,081

Standard Deviation0.22

R-Squared0.42

Alpha-0.03

Financial Highlights & Ratios

Price to Book (P/B)0.00

Price to Sales (P/S)13.58

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

JW (Cayman) Therapeutics Co. Ltd. News

PremiumCompany Announcements

JW Cayman Therapeutics Appoints Deloitte as New Auditor

23d ago

PremiumCompany Announcements

JW Therapeutics Announces New Share Grants

3M ago

PremiumCompany Announcements

JW Therapeutics Announces Board Structure

3M ago

PremiumCompany Announcements

JW Therapeutics Announces Board Appointment

3M ago

PremiumCompany Announcements

JW Therapeutics Reports Steady Performance and Cost Savings

3M ago

PremiumCompany Announcements

JW Therapeutics’ Carteyva® Wins Key Approval

3M ago

PremiumCompany Announcements

JW Therapeutics Prepares for Key Board Meeting

3M ago

PremiumCompany Announcements

JW Therapeutics Announces Board Structure

4M ago

See More HK:2126 News >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.05% Mutual Funds

― Other Institutional Investors

99.95% Public Companies and

Individual Investors

Detailed Ownership Overview >

2126 FAQ

What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?

JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.19 and its highest was HK$3.49 in the past 12 months.

What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?

Currently, no data Available

When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?

JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Mar 19, 2025 which is in 116 days.

How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?

JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 28, 2024. The company reported -HK$0.623 earnings per share for the quarter, beating the consensus estimate of -HK$0.688 by HK$0.064.

Is JW (Cayman) Therapeutics Co. Ltd. overvalued?

According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?

JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.

What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?

JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?

JW (Cayman) Therapeutics Co. Ltd. has 415,436,280 shares outstanding.

What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?

JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.623 in its last earnings report, beating expectations of -HK$0.688. Following the earnings report the stock price went up 1.527%.

Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?

Currently, no hedge funds are holding shares in HK:2126

---

JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score

Unlock Smart Score

Technicals

Fundamentals

Return on Equity

-34.81%

Trailing 12-Months

Asset Growth

-25.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

JW (Cayman) Therapeutics Co. Ltd.

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

---

2126 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"HK$6","-1":"-HK$1","0.75":"HK$0.75","2.5":"HK$2.5","4.25":"HK$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Nov<br/>2023","25":"Nov<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.5,2.3076923076923075,2.1153846153846154,1.923076923076923,1.7307692307692308,1.5384615384615383,1.346153846153846,1.1538461538461537,0.9615384615384615,0.7692307692307692,0.5769230769230769,0.3846153846153846,0.19230769230769207,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.5,2.3076923076923075,2.1153846153846154,1.923076923076923,1.7307692307692308,1.5384615384615383,1.346153846153846,1.1538461538461537,0.9615384615384615,0.7692307692307692,0.5769230769230769,0.3846153846153846,0.19230769230769207,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.5,2.3076923076923075,2.1153846153846154,1.923076923076923,1.7307692307692308,1.5384615384615383,1.346153846153846,1.1538461538461537,0.9615384615384615,0.7692307692307692,0.5769230769230769,0.3846153846153846,0.19230769230769207,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.52,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.35,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.43,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.46,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.65,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.26,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.97,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.57,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.82,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.26,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.07,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.14,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >